

NEW RELEASE COMING SOON

# PHARMACOEPIDEMIOLOGY

## and Therapeutic Risk Management

ISBN 978-0-929375-30-4/Paperbound/xxvi + 1050 pp./2008/\$339

Edited by Abraham G Hartzema, Hugh H Tilson, and K Arnold Chan

The first book incorporating therapeutic risk management as an extension of pharmacoepidemiology, featuring contributions from the world's leading experts.

### TABLE OF CONTENTS

---

1	The Contribution of Pharmacoepidemiology to the Study of Drug Uses and Effects, and Risk Management	17	Randomized Studies in General Practice Databases	29	The Story of Cisapride and Its Withdrawal from the Market: A Case Study
2	Epidemiology in Drug Development	18	Assessing the Validity of Diagnostic Data in Large Administrative Healthcare Utilization Databases	30	Dofetilide Case Study Outline
3	An Overview of the Drug Approval Process: An FDA Perspective	19	Automated Databases in Pharmacoepidemiologic Studies	31	Rotavirus Vaccines
4	The Mandate of the European Medicines Evaluation Agency	20	Drug Safety, Pharmacoepidemiology, and Regulatory Decision-Making	32	Advanced Pharmacoepidemiologic Reasoning: The Story of Second- and Third-Generation Oral Contraceptives: The Story of the Transnational Study on Oral Contraceptives and the Health of Young Women
5	Pharmacovigilance	21	Risk Management in the European Union	33	Pharmacoepidemiology of Asthma Deaths
6	Prescription Event Monitoring in the United Kingdom	22	Risk Perception and Risk Communications: Their Application to Drug Safety	34	Pharmacoepidemiology of Psychiatric Disorders
7	Drug Utilization Research	23	Therapeutic Risk Management Interventions: Feasibility and Effectiveness	35	Pharmacoepidemiology of Vaccines
8	Prescribing Quality Indicators	24	Evaluation of Therapeutic Risk Management Programs	36	Pharmacoepidemiology of Torsade de Pointes
9	Basic Pharmacoepidemiology Methods	25	Medication Errors	37	Drug-Induced Nephrotoxicity
10	Data Mining Techniques in Pharmacovigilance	26	Corporate Risk, Crisis, and Reputation Management: Minimizing Corporate Risks and Responding to Product Crises	38	Pharmacogenetic and Biologic Markers of Unintended Drug Effects
11	Confounding	27	Education and Research on Therapeutics: The Partnership Between Health Services Research and Pharmacoepidemiology	39	The Interface Between Drugs and Devices
12	Propensity Score Analyses in Pharmacoepidemiology	28	Cerivastatin and Rhabdomyolysis	40	Veterinary Pharmacoepidemiology – For the Protection of Human Health
13	Addressing Misclassification in Pharmacoepidemiologic Studies			41	Chronology of Pharmacoepidemiology (1901–2000)
14	Patient-Reported Outcomes: Research and Practices			42	Pharmacoepidemiology: The Future
15	Meta-Analysis of Pharmacoepidemiologic Studies				
16	Pregnancy Registries				

---

HARVEY WHITNEY BOOKS COMPANY

Customer Services: Toll-free 877/PharmD1 (877/742-7631)  
Phone 513/793-3555 • FAX 513/793-3600 • www.hwbooks.com